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Proliferationa b s t r a c t
The main function of Erythropoietin (EPO) and its receptor (EPOR) is the stimulation of erythropoiesis.
Recombinant human EPO (rhEPO) is therefore used to treat anemia in cancer patients. However, clinical
trials have indicated that rhEPO treatment might promote tumor progression and has a negative effect on
patient survival. In addition, EPOR expression has been detected in several cancer forms. Using a newly
produced anti-EPOR antibody that reliably detects the full-length isoform of the EPOR we show that
breast cancer tissue and cells express the EPOR protein. rhEPO stimulation of cultured EPOR expressing
breast cancer cells did not result in increased proliferation, overt activation of EPOR (receptor phosphor-
ylation) or a consistent activation of canonical EPOR signaling pathway mediators such as JAK2, STAT3,
STAT5, or AKT. However, EPOR knockdown experiments suggested functional EPO receptors in estrogen
receptor positive (ERa+) breast cancer cells, as reduced EPOR expression resulted in decreased prolifera-
tion. This effect on proliferation was not seen in ERa negative cells. EPOR knockdown decreased ERa
activity further supports a mechanism by which EPOR affects proliferation via ERa-mediated mecha-
nisms. We show that EPOR protein is expressed in breast cancer cells, where it appears to promote pro-
liferation by an EPO-independent mechanism in ERa expressing breast cancer cells.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
The main and most well described function of erythropoietin
(EPO) is the stimulation of erythropoiesis [1,2] by binding to the
EPO receptor (EPOR), promoting survival, proliferation and differ-
entiation of erythrocytic progenitor cells [3] through the JAK2/
STAT, MAPK and/or the PI3 K pathway [4]. Although EPO and EPOR
were originally believed to have an exclusive role in erythropoiesis,
they are also expressed in many non-hematopoietic cells, for in-
stance in the brain and in the cardiovascular system as well as in
tumors of various origins [5,6], but their functions in these tissues
are not completely known. In brain, EPO exerts tissue-protective
effects on neurons in a paracrine fashion [7] and in the cardiovas-
cular system it protects myocytes against hypoxic injuries [8].
EPOR is expressed in breast cancer cells [9–11] and in breast tumor
endothelial cells [12].The EPOR function in tumor cells remains controversial since
contradicting results have been reported [13,14]. Recombinant hu-
man EPO (rhEPO) and other erythropoiesis-stimulating agents are
used in the treatment of cancer-related anemia although clinical tri-
als have shown an impaired prognosis in patients treated with rhE-
PO [15]. These reports have led to an increased awareness of yet
undeﬁned roles of EPO in tumor growthandprogressionby interact-
ing with EPOR expressed by tumor and stromal cells. We previously
showed a correlation between EPOR expression and tamoxifen re-
sponse and survival in a clinical breast cancermaterial [10]. As EPOR
expression and function in tumor cells have been questioned and
concerns have been raised about the speciﬁcity of available antibod-
ies [10,16], we produced a full-length EPOR speciﬁc antibody to
study the expression and function of EPOR in breast cancer.2. Material and methods
2.1. Cell culture
The EPO-dependent erythroleukemic UT-7 cells (DSMZ, Braun-
schweig, Germany) and breast cancer cell lines (ATCC, Manassas,
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mended by the suppliers. All cell lines were regularly screened
for mycoplasma and replaced by low-passage cells on a tri-
monthly basis.
2.2. Ethics statement
Breast cancer tissues were obtained from patients at Skåne Uni-
versity Hospital, Sweden. Ethical permission was obtained from
the Lund University Regional Ethics Board, Ref. No. 594/2005.
The ethics committee waived the need for patient consent and
expression data were analyzed anonymously.
2.3. Anti-EPOR antibody production and Western blotting
An antiserum towards the C-terminal of human EPOR (hFL-
EPOR) was generated in rabbits using standard procedures. The
EPOR peptide with an added cyctein residue, C-SLIPAAEPLPPS, con-
jugated to keyhole limpet hemocyanin was used as immunogen.
The antibodies were afﬁnity puriﬁed using a column of immobi-
lized peptide antigen as described [17]. Immunoblotting was
performed according to standard procedures. Antibodies are listed
in Supplemental Table S1.
2.4. PCR, RNA interference and cell proliferation assay
Real-time quantitative PCR (RT-qPCR) was performed in tripli-
cates and normalized to three housekeeping genes, SDHA, UBC,
and YWHAZ [18]. Primers are listed in Table S2. For EPOR knock-
down, four different siRNAs were tested (Table S2). Transfection
was performed using Lipofectamin 2000 (Invitrogen) according to
the manufactures’ instructions. Cells were re-seeded in 96-well
plates, 24 h after EPOR knockdown, and proliferation was mea-
sured using WST-1 reagent (Roche).
2.5. Immunoﬂuorescence
Cells transfected with siRNA against EPOR were re-seeded on
coverslips (30,000 cells/ml) and cultured for 48 h under standard
conditions. After ﬁxation and permeabilization the cells were ana-
lyzed for Ki67 immunoreactivity and TUNEL activity by confocal
microscopy as described [19].
2.6. ERE luciferase assay, EPOR plasmid and EPOR over-expression
Cells were seeded at a density of 1  105 cells/well in 12-well
plates and transfected with siRNA against EPOR or control siRNA.
After 24 h the medium was changed to Phenol Red-free medium
supplemented with 10% charcoal stripped serum. After 24 h, cells
were transfected with 1.45 lg pGL2 luciferase reporter plasmid,
pERE-luc (ERa responsive element (ERE), kind gift from Dr. Michael
S. Denison, UCD) and 0.05 mg renilla plasmid pRL-SV40 (internal
control) using Lipofectamin 2000 (Invitrogen), and cultured with
either 10 nM estrogen (17b-estradiol), 1 lM tamoxifen, or both.
Luciferase activity was measured after 24 h using the Dual-Lucifer-
ase Reporter Assay System (DLR) (Promega) and normalized to
internal control.
The Human EpoR cDNA, kindly provided by S. Constantinescu,
was subcloned into the BamHI-EcoRI sites of pcDNA 3.1. An HA
tag was introduced via PCR after the signal peptide, immediately
following amino acid residues PPNL. The cDNA was conﬁrmed by
sequencing. For EPOR over-expression experiments, cells were
transfected with either control siRNA or EPOR siRNA (siEPOR#3)
together with 0.5 mg control (pC) or EPOR (pEPOR) plasmids and
0.5 mg pERE-luc and 0.05 mg renilla plasmids.2.7. Statistical analysis
The error bars represent the SEM from three or more experi-
ments. Statistical analysis were calculated using Student’s t-test
and statistical signiﬁcance was deﬁned as ⁄p < 0.05; ⁄⁄p < 0.01.
3. Results
3.1. EPOR protein expression in breast cancer cells
We generated a rabbit anti-EPOR serum directed towards the C-
terminus and thus, full-length EPOR. The afﬁnity-puriﬁed antibody
(hFL-EPOR) detected a single protein of the anticipated size
(approximately 66 kDa) in the breast cancer cell line CAMA-1
and EPO-dependent erythroleukemic UT7 cells, which served as a
positive control (Figs. 1A and S1A). To further establish that the de-
tected 66 kDa protein was EPOR, we transiently targeted EPOR
expression using siRNA. RT-qPCR and immunoblot analyses clearly
demonstrated a decrease in EPOR mRNA and the 66 kDa protein
amount (Fig. 1A and B). A comparison with the C-20 anti-EPOR
antibody from Santa Cruz, one of the most commonly used com-
mercial anti-EPOR antibodies, showed that both antibodies detect
the EPOR protein but the hFL-EPOR antibody appeared to be more
speciﬁc by generating cleaner blots (Fig. S1A).
Using the hFL-EPOR antibody we detected EPOR expression in
ﬁve tested breast cancer cell lines by immunoblotting (Fig. 1C).
The EPOR expression was conﬁrmed at the mRNA level (Fig. S1B).
EPOR levels did not correlate to ERa protein expression (Fig. 1C).
EPOR protein expression at varying levels was also detected in
three of four tested primary tumor specimens (Fig. S1C).
3.2. Recombinant human EPO does not promote cell growth or
consistently activate canonical EPOR downstream signaling pathways
in breast cancer cells
Stimulation with rhEPO had no effect on growth or viability as
exempliﬁed by CAMA-1, MDA-MB-231 and T47D cells grown under
standard conditions with serum (Fig. 1D). When the experiment
was repeated under serum-free and Phenol Red-free conditions,
rhEPO did not promote cell growth or increased cell survival
(Fig. S2). To investigate the stimulatory capacity of rhEPO, we trea-
ted cells for 10 min with 10 U/ml rhEPO after overnight serum star-
vation. As a positive control UT7 cells were used, where rhEPO
treatment induced phosphorylation of EPORand the canonical EPOR
downstream signaling proteins JAK2, STAT3, STAT5, AKT, and ERK1/
2 (Fig. 1E). Interestingly, in the breast cancer cells, we could not de-
tect phosphorylation of EPOR after rhEPO stimulation using an anti-
phospho-Tyr456 EPOR antibody. We also immunoprecipitated
EPOR from rhEPO-treated ERa+ breast cancer cells, but were unable
to detect phosphorylated EPOR. Of the established signaling media-
tors downstream of EPOR, only ERK1/2 was phosphorylated in ERa+
cells treated for 10 min with rhEPO (Fig. S3A). Interestingly, the ini-
tially high level of AKT phosphorylation (pAKT) decreased slightly in
the rhEPO treated cells, but with a slower kinetics than the increase
in ERK1/2 phosphorylation (Fig. S3A). In rhEPO stimulated MDA-
MB-468 cells, pSTAT3 and pERK1/2 levels increased (Fig. 1E). The
possibility that rhEPO further activates EPOR in breast cancer cells
by slower kinetics or at higher rhEPO concentrations than needed
to activate EPOR in UT7 cells was tested, but uniformly with nega-
tive results (representative data shown in Fig. S3B).
3.3. EPOR knockdown leads to impaired cell proliferation in ERa
positive breast cancer cells
We next knocked down EPOR using siRNA and evaluated the ef-




Fig. 1. Recombinant EPO has no growth promoting effect on EPOR expressing breast cancer cells. (A) EPOR siRNA knockdown show speciﬁcity of the hFL-EPOR antibody. Cells
were transfected with EPOR siRNA (siEPOR1) or control siRNA (C) for 72 h (CAMA) or 24 h (UT7). (B) EPORmRNA levels in UT7 and CAMA-1 cells after EPOR knockdown were
determined by qRT-PCR in triplicates. ⁄=p < 0.05; ⁄⁄=p < 0.01. (C) Immunoblot analysis of EPOR expression in ERa positive (CAMA-1, MCF7 and T47D), ERa negative (MDA-MB-
231, MDA-MB-468) and UT7 cells using the hFL-EPOR antibody. (D) Growth of rhEPO stimulated breast cancer cells. Error bars represent the SEM of three independent
experiments. (E) No consistent activation by rhEPO of canonical EPOR signaling pathways in breast cancer cells. Cells were stimulated with rhEPO (10 U/ml) for 10 min, after
overnight serum deprivation. Phosphorylation of EPOR (pEPOR-Tyr456) and signaling proteins downstream of EPOR (pJAK2-Tyr1007/1006; pSTAT3-Ser272; pSTAT5-Tyr694;
pAKT-Ser473; pERK1/2- Thr202/Tyr204) were detected by immunoblotting. The data are representative for three independent experiments.
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tein level was not as high in CAMA-1 as in UT7 cells (Fig. 1A and
B). Notably, EPOR expression in UT7 cells was more rapidly
knocked-down than in CAMA-1 cells, where the effects of siEPOR
on EPOR protein levels were seen ﬁrst after 48 and 72 h
(Figs. S4A, S4B and S5). The most efﬁcient siRNAs (siEPOR1, siE-
POR3 and siEPOR4) were chosen for further analyses (Figs. S4
and S5).
We found a robust decrease in cell proliferation in ERa+ cell lines
upon EPOR knockdown using different siRNAs (Figs. 2A and S5).
ERa+ cell lines with high EPOR basal levels (CAMA-1 and T47D)
were more affected than cells with a low basal EPOR expression
(MCF7, Figs. 1C and 2A). A putative relation to ERa status was eval-
uated by knocking down EPOR in two ERa negative breast cancer
cell lines. Interestingly, EPOR knockdown did not have any effect
on cell numbers irrespective of whether the basal EPOR level was
high (MDA-MB-231) or low (MDA-MB-468) (Figs. 1C and 2B and
S5). The EPOR knockdown effect on cell number in ERa+ cells was
primarily due to decreased proliferation and not increased cell
death. While the number of TUNEL positive cells was very low in
both control and siEPOR treated CAMA-1 cells (less than 1%,
Fig. 3A), Ki67 expression profoundly decreased after EPOR knock-
down (Fig. 3B). In contrast, when the EPO dependent UT7 cells were
treated with siEPOR most cells died within a 24 h culture period
(Fig. 3A), a result further indicating that the EPOR was indeed tar-geted by the used siRNA. Taken together, the results imply that
EPOR has a function in the growth control of the investigated
ERa+ cells despite that we were unable to detect a growth stimula-
tory effect of rhEPO in these cells. To exclude the possibility that the
EPOR dependent growth of breast cancer cells was driven by endog-
enously produced EPO, we knocked down EPO expression, which
did not affect the growth of ERa+ breast cancer cells (Fig. 2C). Over-
all, EPO mRNA expression in the tested breast cancer cell lines was
low, at the limit of detectability by RT-qPCR, a notion in agreement
with our previous observation that EPO protein is not produced at
detectable levels in the analyzed breast cancer cell lines [10].
3.4. EPOR down-regulation affects ERa activity
Since EPOR knockdown affected proliferation in ERa+ cells, and
in light of our previous results showing that EPOR expression corre-
lates with tamoxifen response, we investigated effects of EPOR
knockdown on ERa activity using an ERE luciferase assay. As ex-
pected, the strong induction of ERa activity upon estrogen stimula-
tion was impaired by tamoxifen treatment in CAMA-1 and T47D
cells (Fig. 4A) and tamoxifen stimulation alone had a slight positive
effect on ERE luciferase activation (Fig. S6A and B). Basal levels of
ERa activity were lower in EPOR knockdown compared to un-
treated cells and estrogen-induced ERa activity was strongly re-
duced upon EPOR knockdown using different siEPORs (Figs. 4A
A B
C
Fig. 2. EPOR knockdown in ERa positive breast cancer cells decreases proliferation. (A, B) EPOR knockdown (siEPOR1) effect on cell number in ERa positive (CAMA-1, MCF7,
T47D) (A) and ERa negative (MDA-MB-231, MDA-MB-468) (B) cells (control siRNA (C)) (⁄p < 0.05; ⁄⁄p < 0.01). Knockdown efﬁciency was determined by immunoblotting. (C)
Knockdown effects of endogenous EPO by siEPO1 and siEPO2 versus siControl on proliferation. Knockdown efﬁciency at the mRNA level is shown in right hand panel.
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ulation induced a 27.9 (±8.4)-fold increase in ERa activity in CAMA-
1 cells whereas in the EPOR knockdown cells the corresponding
increase was 11.8 (±2.2)-fold (p = 0.003). Furthermore, down-regu-
lation of EPOR resulted in a more efﬁcient tamoxifen-induced inhi-
bition of the ERa activity; a 2.9 (±0.9)-fold decrease in ERa activity
in control cells compared to a 3.6 (±0.5)-fold decrease in EPOR
knockdown cells (Fig. 4A, left panel). This result is in concordance
with our previous observation showing an impaired tamoxifen re-
sponse in patients with ERa positive tumors with high EPOR
expression [10]. EPOR knockdown in T47D cells also resulted in a
decreased estrogen-induced ERa activity (33.7 (±14) vs. 14.5 (±4)-
fold induction) while EPOR knockdown did not enhance the effect
of tamoxifen on ERa activity (8.7 (±3.8) vs. 8.1 (±2.9)) (Fig. 4A).
Subsequently, we tested the effect of overexpression of human
wt EPOR on ERa activity. Overexpression of wt EPOR signiﬁcantly
increased ERa activity during estrogen stimulation. Furthermore,
wt EPOR could rescue the siEPOR-inhibited ERa activity (Fig. 4B).
As our data indicated that EPOR is constitutively active via an
EPO-independent process we searched additional support for this
conclusion. We analyzed the effects of EPOR knockdown on phos-
phorylated AKT (pAKT) and in all three ERa+ cell lines pAKT levels
were substantially reduced upon EPOR down-regulation in keeping
with the reduced growth rate of siEPOR-treated cells, while total
AKT protein expression was not affected (Fig. 4C).
4. Discussion
We here show that cultured breast cancer cells express EPOR
but do not respond to rhEPO stimulation by changes in prolifera-tion or survival. Furthermore, using EPO-dependent UT7 erythro-
leukemic cells as a positive control, we could not detect rhEPO-
induced EPOR phosphorylation or a consistently increased
phosphorylation of several mediators of canonical EPOR signal
transduction pathways. Our previous observations that EPOR
expression levels, analyzed in a large breast cancer material, hold
prognostic information and that tamoxifen sensitivity in ERa+ tu-
mors could be related to low EPOR expression [10], inferred that
EPOR in breast cancer cells mediates not yet deﬁned biological re-
sponses. Here, we report that knocking down EPOR in ERa+, but not
in ERa negative breast cancer cells, resulted in growth inhibition
but not cell death. EPOR expression was associated with estro-
gen-induced ERa activity as activation levels decreased in EPOR
knocked-down ERa+ cells. In these cells EPOR appears to be consti-
tutively active, leading to high AKT activity as demonstrated by de-
creased pAKT levels after EPOR knockdown. Thus, our data suggest
that EPOR has a role in proliferation control of ERa+ breast cancer
cells while cell survival seems to be unaffected by reduction of
EPOR expression.
Stimulation with rhEPO did not result in increased proliferation
or survival in the ﬁve tested breast cancer cell lines, which is in
keeping with recent published data showing that EPOR expressing
breast cancer cells do not respond by growth to rhEPO stimulation
[20], although contradictory ﬁndings have been reported [9]. Pub-
lished data do however demonstrate that rhEPO stimulation of
breast cancer cells results in changes in cell signaling mediators
such as AKT, ERK1/2 and STATs [14,21,22] and here we present
data showing that rhEPO stimulation can increase both ERK1/2
and STAT3 phosphorylation in some of the tested cell lines. Also,


























Fig. 3. Downregulation of EPOR results in growth arrest but not increased cell death. TUNEL (A) and immunoﬂuorescence staining of Ki67 (B) in EPOR knocked-down CAMA-




Fig. 4. EPOR interferes with ERa signaling. (A) Cells transfected with pERE luciferase reporter construct and treated with siRNA (siEPOR1 or siC), were stimulated for 24 h
with 10 nM estrogen (E2) and/or 1 lM tamoxifen (TAM). SEM of four different experiments. (B) EPOR overexpression in CAMA-1 cells reverts the inhibitory effect of siEPOR
on estrogen-induced ERE luciferase activity. Right panel shows EPOR protein levels in cells transfected with control (pC) and EPOR (pEPOR) plasmids. (C) The expression of
EPOR and phosphorylation status of AKT in ERa+ breast cancer cells 72 h after EPOR1 treatment (c; siRNA control).
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that change the phosphorylation, and presumably activation status
of AKT. The growth-inhibiting effect of knocking down the EPOR
receptor was restricted to the ERa+ breast cancer cells and did
not require prior activation of EPOR by rhEPO. Thus, the growthpromoting activity of EPOR seems to be constitutive in the tested
ERa+ cells. The fact that the two studied ERa negative breast cancer
cell lines also express EPOR suggests that this receptor has
additional functions in these and presumably also in ERa+ cells.
Although our study focuses on the growth-promoting effect of
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PO/EPOR signal transduction complex induces other biological re-
sponses like cell migration and cell survival gene expression [21].
The rhEPO-stimulated increase in ERK and STAT3 phosphorylation
in a cell line-dependent manner, seen here and emphasized by
more extensive published data on rhEPO activated signal transduc-
tion mediators [14,21,22], do suggest a broader role of rhEPO/EPOR
in breast cancer and that EPOR signaling is not restricted to prolif-
eration control in ERa+ cells.
EPOR expression in clinical breast cancer specimens correlates
to outcome [10] and rhEPO treatment of ERa negative xenograft
tumors does not affect primary tumor growth but promotes metas-
tasis [23], indicating that EPOR mediates speciﬁc, but not yet fully
deﬁned activities also in vivo. In ovarian cancer cells, EPOR is con-
stitutively active and signals through classical pathways deter-
mined by the activation of the signal transduction mediators JAK,
STAT, AKT and ERK. Interestingly, in these cells, EPOR knockdown
resulted in reduced proliferation and invasiveness in an EPO-inde-
pendent way [24,25]. The difference in EPOR turnover revealed to
us by the EPOR knockdown experiments in breast cancer versus
hematopoietic cells might suggest a different EPOR biology in these
two cell types. This dissimilarity in turnover rates could be ex-
plained by a difference in activation mechanisms. While rhEPO-in-
duced receptor activation in UT7 cells preferentially triggers
classical internalization and processing via the lysosomal system,
EPOR in breast cancer cells might circumvent these pathways.
The explanation could be that the EPORs in breast cancer cells
are not exposed at the cell surface and thus have another subcellu-
lar localization than in UT7 cells [20]. This scenario would also ex-
plain why rhEPO robustly triggers EPOR signaling in UT7 but not in
the breast cancer cells analyzed.
An interesting observation presented here is the suggested link
between EPOR expression and ERa activity. While EPOR knock-
down diminished the proliferation of ERa+ breast cancer cells, this
effect was not seen in ERa negative cells. We also observed that
EPOR knockdown signiﬁcantly decreased ERa activity in ERa+
breast cancer cells. This observation provides an explanation of
the impact of EPOR on proliferation since the ERa-pathway is a po-
tent regulator of proliferation in ERa+ breast cancer cells [26]. The
detailed molecular explanation as to how EPOR can modify ERa
activity remains to be established. Our data however indicate that
the PI3 K-AKT pathway is constitutively activated by EPOR in the
investigated cells, an observation that should be further explored.
Data presented here also support our previously published
observations on EPOR expression in relation to tamoxifen re-
sponse in patients with ERa+ tumors in a clinical trial. In that
study, patients with tumors having high EPOR expression were
less responsive to tamoxifen treatment compared to those with
low EPOR expression [10]. These observations are supported by
the EPOR knockdown effects in CAMA-1 cells, which resulted in
a more efﬁcient tamoxifen-induced inhibition of ERa activity.
The observed putative link between low EPOR expression and
improved efﬁciency of tamoxifen has potential relevance in the
clinical setting. One can envision a situation where blocking EPOR
in breast cancer cells could increase the treatment efﬁciency of
tamoxifen, perhaps by counteracting tamoxifen resistance. The
molecular explanations for the interactions between EPOR and
ERa activity might also unravel mechanisms of tamoxifen
resistance, questions that need to be addressed in order to ﬁnd
out how EPOR should be targeted to modulate the potent ERa
signaling pathways in breast cancer.
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